COVID-19 outcomes in sickle cell disease and sickle cell trait
Authors:
- 7 September 2022
- journal article
- research article
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 35 (3) , 101382
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
- Teva Pharmaceutical Industries
- American Society of Hematology
This publication has 50 references indexed in Scilit:
- Sickle cell diseaseThe Lancet, 2017
- Sickle Cell DiseaseNew England Journal of Medicine, 2017
- Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortalityBritish Journal of Haematology, 2017
- Sickle Cell Trait, Rhabdomyolysis, and Mortality among U.S. Army SoldiersNew England Journal of Medicine, 2016
- Sickle cell trait diagnosis: clinical and social implicationsHematology-American Society Hematology Education Program, 2015
- Mortality Rates and Age at Death from Sickle Cell Disease: U.S., 1979–2005Public Health Reports®, 2013
- Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to knowJournal of Thrombosis and Thrombolysis, 2013
- Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell diseasePediatric Blood & Cancer, 2007
- Principles and problems of transfusion in sickle cell diseaseSeminars in Hematology, 2001
- Mortality In Sickle Cell Disease -- Life Expectancy and Risk Factors for Early DeathNew England Journal of Medicine, 1994